OYST News and Press, Oyster Point Pharma Inc. From 03/02/21

The FDA has accepted Oyster Point Pharma's (OYST) New Drug Application ((NDA)) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease.The PDUFA target action date is October 17.At present, FDA has stated that it does not intend to hold an advisory commi...

Prescription Drug User Fee Act ( PDUFA) target action date is October 17, 2021 U.S. Food and Drug Administration (FDA) has stated that it does not intend to hold an advisory committee meeting to discuss this application Planned U.S. launch of OC-01 (varenicline) nasa...

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

The following slide deck was published by Oyster Point Pharma, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Oyster Point Pharma, Inc. 2020 Q4 - Results - Earnings Call Presentation

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q4 2020 Earnings Call Feb 18, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q4 2020 Earnings Call Transcript...

Oyster Point Pharma, Inc. (OYST) Q4 2020 Earnings Conference Call February 18, 2021, 04:30 PM ET Company Participants Daniel Lochner - CFO Jeffrey Nau - President and CEO John Snisarenko - Chief Commercial Officer Conference Call Participants Anupam Rama - JPMorgan Tara Bancroft - Piper Sandl...

Oyster Point Pharma (OYST): Q4 GAAP EPS of -$0.86 misses by $0.07.As of December 31, 2020, cash and cash equivalents were $192.6M, compared to $139.1M as of December 31, 2019.Press Release For further details see: Oyster Point Pharma EPS misses by $0.07

OC-01 (Varenicline) Nasal Spray New Drug Application (NDA) Submitted to the U.S. Food and Drug Administration (FDA) for the Treatment of Signs and Symptoms of Dry Eye Disease on December 17, 2020 Phase 2 Clinical Trial Protocol of OC-01 (Varenicline) Nasal Spray in Patients with...

PRINCETON, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...